Gimv and EdRip back Complix with €12m

Co-investment in the round was provided by Finnish fund Biotech Fonds Vlaanderen, biotech firm Ablynx, biopharmaceutical company Actogenix, crop protection firm Agrosavfe, molecular genetics company Multiplicom and Pronota, a biotech business.

The investment is the sixth completed by the investor consortium.

The funding will facilitate the development of a first set of therapeutics for the treatment of cancer and autoimmune indications. 

Previous funding
In 2010, Complix raised €5m in a series-A round from Vesalius Biocapital and LRM, investing alongside the Luxembourg-based Public Research Centre for Health (CRP Santé).

Company
Founded in 2008 and based in Hasselt, Belgium, Complix has research facilities in Ghent and Luxembourg. The business is focused on the development of protein therapeutics for oncology and autoimmunity. The firm's therapeutics, Alphabodies, combine features of antibodies with the benefits of small chemical drugs, expanding the range of diseases Alphabodies can tackle to include those that had otherwise been untreatable.

People
Patrick Van Beneden is a partner at Gimv and worked on the deal. He joins the Complix board alongside Gilles Nobécourt from EdRip.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Expansion
• Belgium
• Gimv
• Andera Partners